Susquehanna International Group’s BriaCell Therapeutics Warrant BCTXL Stock Holding History

Susquehanna International Group’s Portfolio BCTXL Stock Details BCTXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$23.9K	Buy	+23,889	New	+$25.3K	﹤0.01%	12821

Other funds holding BCTXL

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

EAM

Empery Asset Management New York $83M AUM

HCM

Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return

MYDA Advisors Woodmere, New York $608M AUM 77.08% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

WAM

Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

Susquehanna International Group's BCTXL Position: Q1 2026 in Review

Susquehanna International Group opened a new position in BriaCell Therapeutics Warrant (BCTXL) in Q1 2026: 23,889 shares worth $23.9K. The stake represents ﹤0.01% of the portfolio and ranks #12821 among its holdings.

15 funds tracked by Wall St. Rank hold BCTXL as of Q1 2026.

Susquehanna International Group held 23,889 shares of BriaCell Therapeutics Warrant worth $23.9K as of Q1 2026.
BriaCell Therapeutics Warrant was a new Susquehanna International Group position in Q1 2026.
BriaCell Therapeutics Warrant made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #12821 holding.
15 funds tracked by Wall St. Rank held BriaCell Therapeutics Warrant as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.